Thursday, April 30, 2026

FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity

›
Federal regulators on Wednesday approved Eli Lilly's new weight-loss pill, a second daily oral medication to treat obesity and other wei...
Wednesday, April 29, 2026

Study Details | NCT07506044 | Dexmedetomidine as an Adjuvant During Dural Puncture Epidural

›
In continuation of my update on Dexmedetomidine Study Overview Brief Summary: The study aimed to determine the effects of using varied doses...
Tuesday, April 28, 2026

Study Details | NCT07506395 | Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

›
In continuation of my update on  Psilocybin This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-forma...
Monday, April 27, 2026

Finerenone shows superior survival and kidney protection over spironolactone in diabetic kidney disease

›
In continuation of my update on  Finerenone Researchers from National Taiwan University Hospital and collaborating institutions have demonst...
Friday, April 24, 2026

Daily coffee drinking may slow biological aging of people with major mental illness

›
In continuation of my update on  coffee Drinking a maximum of 3–4 cups of coffee a day may slow the "biological" aging of people w...
Wednesday, April 22, 2026

Johnson & Johnson Seeks First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

›
Johnson & Johnson (NYSE: JNJ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (F...
Thursday, April 16, 2026

ACC: Mavacamten Efficacious for Adolescents With Obstructive Hypertrophic Cardiomyopathy

›
In continuation of my update on  Mavacamten Mavacamten, the first-in-class cardiac myosin inhibitor approved for treatment of symptomatic ad...
Wednesday, April 15, 2026

AAD: Significant Benefits Seen for Brepocitinib 30 mg in Dermatomyositis -

›
For adults with  dermatomyositis , brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a ...
Saturday, April 11, 2026

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

›
Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food and Drug Administration (FDA) has...
Friday, April 10, 2026

Much-needed new drug approved for deadliest blood cancer (ziftomenib)

›
Biomedical research that began at the University of Virginia School of Medicine has yielded a much-needed new treatment for patients with th...
Wednesday, April 8, 2026

PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA

›
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter...
Thursday, April 2, 2026

FDA Accepts Shionogi’s Ensitrelvir NDA for Review as the First Oral Therapy for the Prevention of COVID-19 Following Exposure

›
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the U.S...
Wednesday, April 1, 2026

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

›
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercializ...
Thursday, February 19, 2026

Sentynl Therapeutics Updates, Complete Response Letter (CRL) relating to its New Drug Application (NDA) for On Its NDA for CUTX-101

›
Sentynl Therapeutics, Inc. (“Sentynl”), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (“Zydus”), announced...
Wednesday, February 18, 2026

FDA Approves Linzess (linaclotide) for Children 7 Years and Older with Irritable Bowel Syndrome with Constipation

›
The U.S. Food and Drug Administration (FDA) has approved Linzess (linaclotide) capsules for pediatric patients 7 years and older with irrita...